Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) Meeting Abstract
| Authors: | Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; Burke, M.; Ralabate, A.; Rivera, A.; Kronenberg, S.; Agunwamba, B. U.; Feely, W.; Hong, Q.; Krishnan, S.; Wolchok, J. |
| Abstract Title: | Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) |
| Meeting Title: | 39th ESMO Congress (ESMO 2014) |
| Journal Title: | Annals of Oncology |
| Volume: | 25 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2014 Sep 26-30 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2014-09-01 |
| Start Page: | iv374 |
| Language: | English |
| ACCESSION: | WOS:000346901000314 |
| DOI: | 10.1093/annonc/mdu344.1 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1085O -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work